759 related articles for article (PubMed ID: 27044276)
1. Correlation between optic nerve head circulation and visual function before and after anti-VEGF therapy for central retinal vein occlusion: prospective, interventional case series.
Nagasato D; Mitamura Y; Semba K; Akaiwa K; Nagasawa T; Yoshizumi Y; Tabuchi H; Kiuchi Y
BMC Ophthalmol; 2016 Apr; 16():36. PubMed ID: 27044276
[TBL] [Abstract][Full Text] [Related]
2. Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy.
Toto L; Evangelista F; Viggiano P; Erroi E; D'Onofrio G; Libertini D; Porreca A; D'Aloisio R; Mariacristina P; Di Antonio L; Di Nicola M; Mastropasqua R
Biomed Res Int; 2020; 2020():9496242. PubMed ID: 32104710
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
4. Ocular microcirculation changes, measured with laser speckle flowgraphy and optical coherence tomography angiography, in branch retinal vein occlusion with macular edema treated by ranibizumab.
Asano T; Kunikata H; Yasuda M; Nishiguchi KM; Abe T; Nakazawa T
Int Ophthalmol; 2021 Jan; 41(1):151-162. PubMed ID: 32894391
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL;
Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476
[TBL] [Abstract][Full Text] [Related]
6. Retinal blood flow levels measured by laser speckle flowgraphy in patients who received intravitreal bevacizumab injection for macular edema secondary to central retinal vein occlusion.
Matsumoto M; Suzuma K; Fukazawa Y; Yamada Y; Tsuiki E; Fujikawa A; Kitaoka T
Retin Cases Brief Rep; 2014; 8(1):60-6. PubMed ID: 25372211
[TBL] [Abstract][Full Text] [Related]
7. RETINAL BLOOD FLOW CORRELATES TO AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR IN CENTRAL RETINAL VEIN OCCLUSION.
Yamada Y; Suzuma K; Matsumoto M; Tsuiki E; Fujikawa A; Harada T; Kitaoka T
Retina; 2015 Oct; 35(10):2037-42. PubMed ID: 25932555
[TBL] [Abstract][Full Text] [Related]
8. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
Ehlers JP; Decroos FC; Fekrat S
Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
[TBL] [Abstract][Full Text] [Related]
10. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion.
Sacu S; Pemp B; Weigert G; Matt G; Garhofer G; Pruente C; Schmetterer L; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3046-50. PubMed ID: 21051706
[TBL] [Abstract][Full Text] [Related]
11. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
[TBL] [Abstract][Full Text] [Related]
12. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
15. Early bevacizumab treatment of central retinal vein occlusion.
Ferrara DC; Koizumi H; Spaide RF
Am J Ophthalmol; 2007 Dec; 144(6):864-71. PubMed ID: 17916320
[TBL] [Abstract][Full Text] [Related]
16. Changes in retinal blood flow in patients with macular edema secondary to branch retinal vein occlusion before and after intravitreal injection of bevacizumab.
Nagaoka T; Sogawa K; Yoshida A
Retina; 2014 Oct; 34(10):2037-43. PubMed ID: 24896136
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
